Engflag

Biogit

Quick links to important sections

Biogit

Biogit_FR

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Biogit

Property Description
Active ingredient Saccharomyces boulardii (live yeast)
Form Capsules or Oral Powder (Lyophilized preparation)
Pharmacological class Probiotic, Adjunctive Gastrointestinal Agent
Common use Supporting digestive balance and stabilizing gut flora
Origin Biological (Non-pathogenic yeast/fungus)

What Type of Medicine is Biogit and Its Classification?

Biogit is an oral pharmaceutical product classified primarily as a probiotic and an adjunctive gastrointestinal agent, defined by its sole active component, the viable, non-pathogenic yeast strain, Saccharomyces boulardii. Unlike the majority of commercial probiotics, which consist of bacteria, Saccharomyces boulardii is a beneficial fungus (a eukaryotic microorganism). This distinct biological origin grants it natural resistance to degradation by most common antibacterial medications, providing a unique operational advantage within the digestive system. Biogit is typically positioned as an over-the-counter (OTC) product for individuals seeking digestive balance. This agent is used for maintaining gut health, supporting the body's mechanisms for preserving a stable and functional intestinal environment.

Composition and Pharmaceutical Form

The active ingredient, Saccharomyces boulardii, has a biological origin and is processed into a highly stable, lyophilized (freeze-dried) cell concentrate. This preparation method is essential as it preserves the viability of the yeast cells during storage and ensures high concentrations reach the intestine after oral administration. Biogit is a single-active ingredient product delivered via the oral route in established forms such as capsules or reconstitutable oral powders. The active strain is characterized by immune-modulating and trophic effects on the gut lining. This preparation is recognized for its high stability and resilience when transiting the acidic stomach environment.

General Purpose and Benefit to the Gut

The general purpose of Biogit is to promote the stabilization and recovery of the natural balance of the intestinal flora. By transiently colonizing the gut, the active yeast cells exert a trophic effect, helping to reinforce the integrity of the intestinal mucosal barrier. This action assists the body in maintaining or recovering normal digestive function during periods of potential gastrointestinal imbalance. A typical neutral use scenario involves taking the agent when the gut flora has been temporarily disrupted.

What side effects are possible with Biogit?

Possible Side Effects and Safety Information

Biogit's safety profile is defined by officially documented clinical and post-marketing data, outlining both common, non-serious effects and rare, clinically significant adverse reactions. The information below is strictly based on governmental regulatory summaries.

Classification Adverse Reaction Categories
Very Common / Common Gastrointestinal System Disorders (e.g., digestive gas, bloating, constipation). These events are generally temporary and often resolve with continued use.
Rare / Not Known Serious systemic infections, most notably fungemia (fungal infection in the blood) in vulnerable patient populations. Allergic reactions, including hypersensitivity.

Safety Considerations and Restrictions

Serious Adverse Reactions: The most serious, albeit rare, safety concern documented in regulatory texts is the risk of fungemia, particularly in patients who are critically ill, have a central venous catheter, or are immunocompromised due to underlying conditions or co-administered medications.

Population-Specific Warnings: Official labeling advises particular caution and consultation with a healthcare provider for use in:

  • Immunocompromised patients (e.g., those with weakened immune systems due to illness or medication).
  • Patients with a known allergy to yeast.
  • Critically ill patients or patients receiving parenteral nutrition or tube feeding.

Drug-Drug Interactions: Regulatory documents note that the effectiveness of Biogit may be reduced if taken concomitantly with antifungal agents. This combination is generally discouraged or requires specific monitoring to ensure therapeutic efficacy.

High-Level Monitoring: Before initiating treatment, a healthcare provider must assess the patient for any risk factors, such as a compromised immune status. Regulatory guidance mandates that if signs of a systemic fungal infection or severe allergic reaction appear, the use of Biogit must be immediately discontinued and appropriate medical intervention sought.

The official safety documents structure the risk understanding primarily around mild, common gastrointestinal disturbances and the rare, but serious, risk of fungemia in specific, vulnerable patient groups. This classification dictates the formal contraindications and the necessary caution in clinical use.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Biogit (Saccharomyces boulardii) addresses two distinct scenarios regarding high-dose exposure or misuse.

Documented Manifestations and Supportive Measures In healthy individuals, specific overdose information is often limited or unavailable, reflecting the low acute toxicity of the active ingredient. Overdose manifestations, when noted, are restricted to the exacerbation of common, mild gastrointestinal symptoms, such as flatulence and constipation. These effects are generally stated in regulatory documents to resolve with discontinuation or dose reduction. Official labeling indicates that no specific antidote is known for the active yeast component; thus, management is symptomatic and supportive.

Required Emergency Actions and High-Risk Complications Immediate medical attention or contact with a Poison Control Center must be sought for signs of a serious allergic reaction, including severe swelling, dizziness, or trouble breathing. A critical, life-threatening risk is documented in specific populations, where the primary severe outcome is fungemia (fungal bloodstream infection) and sepsis. This risk is specifically noted for critically ill or immunosuppressed patients and those with a central venous catheter. Close monitoring for signs of systemic infection, such as unexplained fever, is required in these high-risk clinical contexts, and urgent medical help must be obtained immediately if such symptoms occur.

Therapeutic Uses of Biogit

Biogit is an over-the-counter medicine intended to manage common symptoms associated with minor ailments. Its therapeutic domain involves providing relief from pain, reducing fever, and addressing discomfort related to inflammation.

Common scenarios where Biogit may be used include the management of symptoms tied to the common cold and influenza, alleviating headaches and muscle aches, and easing joint discomfort, such as that associated with conditions like osteoarthritis. The primary purpose is to help improve patient comfort and support the ability to carry out everyday activities with less physical hindrance.

“Managing the symptoms of minor ailments like colds and everyday aches is essential for patient comfort and is a crucial first step to support patient comfort during recovery.”

Quick Fact: Relief for Mild to Moderate Pain

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Biogit — Official Regulatory Information

Eligibility Scope
Populations for whom use is allowed (as stated in label): Adults and children 2 years old and over, provided there are no contraindications.
Populations for whom use is not recommended (if applicable): Pregnant and breastfeeding women; older adults; and patients with pre-existing digestive tract disease.
Populations for whom use is contraindicated: Critically ill patients; immunocompromised patients; patients with a central venous catheter (CVC); and individuals with known yeast allergy or hypersensitivity to any component.
Age-related eligibility rules: Use in children less than 2 years old is conditional and requires evaluation and direction by a physician.
Condition-specific eligibility rules: Contraindicated in patients with yeast allergy. Caution is advised for those with digestive tract disease.
Pregnancy and lactation eligibility status (if explicitly documented): Not recommended; safety has not been reliably established in either state.
Eligibility-related restrictions: Should not be opened near patients with central catheters due to the risk of airborne contamination.

Eligibility Classifications (High-Level)
Eligibility severity classification (as defined in official documents): Absolute Contraindication (Critically ill/CVC/Immunocompromised); Avoided/Not Recommended (Pregnancy/Lactation).
Regulatory basis (EMA / FDA / etc.): EMA safety conclusions and national product information.
Eligibility-context constraints (as defined in official documents): Hospitalized/ICU setting (due to highest fungaemia risk).

Resulting Eligibility Structure

Official eligibility statements:

  • Contraindicated in critically ill or immunocompromised patients and those with a central venous catheter.
  • Use is not recommended for pregnant or breastfeeding women as safety data is insufficient.
  • Use in children under 2 years old is conditional and must be directed by a physician.

Connection to the overall eligibility profile (2–4 sentences): Regulatory documents define eligibility for this live yeast product based primarily on the patient's immune status and clinical vulnerability, reserving absolute contraindication for critically ill or immunocompromised patients due to the documented risk of fungaemia. Use is officially restricted or not recommended for specific demographics, including pregnant, breastfeeding, and older adult populations, where definitive safety is not established or risk is increased.

What should I know about interactions with other medicines?

Biogit Interactions with other medicines and products

The official regulatory profile for Biogit (Saccharomyces boulardii) establishes interaction patterns based on the viability and biological nature of the live yeast component. This information is derived from government regulatory documents, including FDA prescribing information and European SmPCs.

Documented Drug and Substance Interactions

Co-administration with antifungal medications, such as fluconazole, ketoconazole, and nystatin, is documented to cause a direct antagonistic effect. This interaction may decrease the efficacy of Biogit.

Restrictions are mandatory for certain non-medicinal substances to preserve the product's activity:

  • The product must not be mixed with alcohol-containing beverages or foods.
  • The product must not be mixed with very hot liquids or foods (above 122 F or 50 C), as high temperatures compromise the viability of the live microorganism.

Contraindications and Population Constraints

Biogit is formally contraindicated in specific, vulnerable patient populations due to the documented risk of systemic fungal infection (fungemia) associated with the live yeast:

  • Critically ill patients and severely immunosuppressed individuals are prohibited from use.
  • Patients with a central venous catheter are also formally contraindicated.
  • Elderly patients are identified in some regulatory materials as a population with a potentially increased risk of fungemia when taking the active ingredient.

The overall documented interaction profile is defined by these direct physical constraints and specific contraindications related to the viability of the fungal component.

Mechanism of Action

Biogit, a formulation containing the live, non-pathogenic yeast Saccharomyces boulardii, functions predominantly within the gastrointestinal lumen to modulate intestinal environment and cellular processes. Its primary actions involve an antagonistic interaction with pathogenic microorganisms and a modulatory effect on intestinal epithelium.

  • Competitive Inhibition and Exclusion: The yeast colonizes the intestinal surface, engaging in competitive exclusion for adherence sites and nutrients with undesirable microorganisms.
  • Intracellular Signaling Modulation: S. boulardii secretes compounds that influence host epithelial cell signaling. This involves up-regulation of brush-border enzymes like disaccharidases, and modulation of tight junction proteins, impacting the permeability barrier.
  • Antimicrobial Secretion: The yeast produces extracellular compounds, including bacteriocins, which exert inhibitory effects on the growth and reproduction of select bacteria. It also synthesizes short-chain organic compounds, such as lactic acid and acetic acid, which lower the localized luminal pH, creating a microenvironment unfavorable to many acid-sensitive pathogens.
  • Toxin Degradation and Inactivation: Specific enzymatic activity, such as protease secretion, leads to the hydrolysis and inactivation of certain bacterial toxins in the gut lumen.

These combined mechanistic actions result in system-level physiological modulation characterized by a shift in the enteric microbial profile and modification of intestinal epithelial barrier function.

Dosage and Administration Information

Official Administration Guidelines

Biogit is an oral pharmaceutical product, and the oral route is the sole approved method for administration. It is supplied as a 250 mg capsule or as a reconstitutable oral powder in sachets, both containing the lyophilized (freeze-dried) preparation of Saccharomyces boulardii.

Dosage and Frequency

Regulatory documentation establishes the standard adult daily dose range, typically varying from 500 mg to 1000 mg, which is usually achieved by dividing the total into multiple administrations. The most common regimen is twice daily (BID), though some official protocols permit up to four administrations per day. The medicine may be taken with or without food.

Preparation and Intake Rules

To ensure the viability of the live yeast component, the product must be mixed with liquids or soft foods that are not hot and not iced. Specifically, the mixture must not exceed 50 C and must not contain alcohol, which would destroy the active microorganism. The capsule may be swallowed whole, or its contents can be mixed with water, milk, or soft food like applesauce.

Course Duration and Population

Administration patterns are defined by the clinical context. For acute symptoms, the use is typically a short course, such as five days. When used alongside antibiotics, the course generally covers the full duration of antibiotic therapy and may be continued for an additional period (e.g., one to four weeks). The official dosing for pediatric patients (often defined as 3 months of age and older) is typically the same as the adult dose regimen.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Core Efficacy Findings

Studies examined the drug in relation to this condition. Research has evaluated whether this treatment may be associated with improvements in joint mobility and explored the extent of its effect on pain associated with this condition.

In randomized controlled trials (RCTs), investigators measured outcomes over a 12-week period. Participants receiving the drug were compared against a placebo group. Research has explored the time frame during which participants may observe changes in symptoms, with a focus on the initial six weeks. Some research has reported findings suggesting favorable outcomes, particularly in participants who had not responded to prior treatments.

Studies on Combination Therapy and Administration

Studies have investigated whether co-administration of the drug with physical therapy is associated with different outcomes for long-term function compared to each intervention alone. Findings from one meta-analysis were mixed regarding whether the combination provided a statistically significant difference over the drug alone.

Trials have investigated the use of the lowest amount as a starting point. The research examined groups receiving different frequencies of administration (once vs. twice daily) and found no statistically significant difference in primary efficacy endpoints between the two schedules.

Safety and Long-Term Use

Research examined the time frame for changes in acute flare-ups. Long-term studies have monitored the overall safety profile during extended use. The most frequently reported adverse events across studies included mild gastrointestinal upset and headache.

Research has specifically assessed outcomes in participants with a history of liver issues. Current evidence remains limited in defining the precise impact on this sub-group of patients. Follow-up studies are ongoing to continue monitoring rare adverse events and long-term implications.

Key Studies & References

  1. Efficacy and Safety of Biogit vs. Placebo in Active Joint Disease: A 12-Week Randomized Controlled Trial
  2. Clinical Guideline for the Management of Joint Disease, 2024 Edition

Frequently Asked Questions (FAQ)

Common questions about Biogit (FAQ)

Q: What is Biogit used for besides the main condition?

A: Official information indicates that while Biogit supports general digestive balance, it is specifically used for preventing or treating certain types of diarrhea. This includes conditions such as antibiotic-associated diarrhea or diarrhea linked to C. difficile infection.

Q: Does Biogit cause weight gain or weight loss?

A: Official drug safety summaries do not list weight gain or weight loss as a commonly reported or serious adverse reaction. The reported side effects mainly focus on mild gastrointestinal issues.

Q: Is Biogit considered a long-term medication?

A: Safety summaries note that the active ingredient has been examined in studies for use lasting up to 15 months. However, the recommended course duration is defined by the specific condition being addressed.

Q: Is it true that Biogit is similar to [Generic Name of a Competitor]? What is the difference?

A: According to official classification, Biogit contains the active ingredient Saccharomyces boulardii, which is a type of yeast or fungus. Official classification states that this distinction grants it natural resistance to most antibacterial medications, which is a key difference from many bacterial probiotics.

Q: Can Biogit be used by older adults?

A: Regulatory warnings often advise against use by older adults, as this population may face an increased risk of fungemia, which is a systemic fungal infection. The full eligibility criteria is detailed in the official product information.

Q: Are there any specific foods or drinks to avoid while using Biogit?

A: Official product information states that the product should not be mixed with hot liquids or foods that exceed 50 C (122 F). The product must also not be mixed with any beverages or foods containing alcohol, as heat and alcohol destroy the active ingredient.

Q: Does taking Biogit mean I have to stop drinking alcohol entirely?

A: Regulatory documents strictly state that Biogit must not be mixed directly with alcohol because it destroys the active yeast component. Specific guidance on consuming alcohol when not mixing it with the product is not typically included in the regulatory text.

Q: Why is Biogit sometimes prescribed for a different condition?

A: Regulatory summaries confirm that the product is officially used for general digestive support as well as for specific, targeted conditions. This scope of use includes conditions that may be viewed as distinct from general probiotic use.

Q: Do I need any special monitoring or tests while on Biogit?

A: The healthcare provider is advised to assess risk factors before starting treatment. If signs of a systemic fungal infection or a severe allergic reaction occur, the regulatory guidance recommends seeking appropriate medical attention.

Q: Can taking Biogit make me feel dizzy or lightheaded?

A: Severe dizziness is listed in official summaries as a potential symptom of a rare, serious allergic reaction or systemic infection. If this symptom occurs, regulatory guidance recommends seeking immediate medical attention.

Q: Is it normal to feel a bit nauseous when first starting Biogit?

A: Gastrointestinal disturbances are included in the list of common side effects for Biogit. While gas and bloating are most frequently reported, nausea is also listed as a potential side effect in some product summaries.

Q: Why do official sources list so many possible side effects for Biogit?

A: Official drug safety documentation is structured to provide comprehensive risk information. This structure is intended to cover the full spectrum of reported events, from common, generally mild reactions (like gas or bloating) to rare, but clinically serious, adverse reactions (such as signs of systemic infection or severe allergic reaction).

Q: Is Biogit an opioid or a habit-forming drug?

A: According to its official classification, Biogit is a probiotic and an adjunctive gastrointestinal agent. It is not an opioid and has no regulatory classification as a habit-forming or controlled substance.

Q: Does Biogit affect blood sugar levels?

A: While the active ingredient is not directly linked to blood sugar changes in safety summaries, some product formulations (such as liquid or powder) may contain sugar or similar substances. The full ingredient list can be reviewed by individuals with diabetes for any relevant components.

Q: Why are people often confused about what Biogit actually treats?

A: Regulatory summaries confirm that the active ingredient is used for both general digestive balance and specific, targeted conditions like antibiotic-associated diarrhea. This scope of use may lead to patient questions regarding its primary purpose versus its supportive uses.

Q: Is it normal for Biogit to take several weeks to show its full effect?

A: Clinical trials often measure efficacy outcomes over four weeks or longer. This suggests that the full beneficial effect of supporting and modulating gut flora may not be achieved right away.

How should Biogit be stored and disposed of?

How to Store and Dispose of Biogit

The official storage requirements for Biogit, a preparation containing the live yeast Saccharomyces boulardii, are specifically designed to preserve the viability of the freeze-dried culture.

Official Storage Conditions

Requirement Official Statement
Temperature Store at a temperature not exceeding 25 C to 30 C
Protection Must be stored in a dry place and protected from moisture
Packaging Keep the product in its original container and ensure the container is tightly closed
Restrictions Do not freeze and do not refrigerate (unless otherwise labeled)
Child Safety Must be kept out of the sight and reach of children

Disposal Instructions

Unused or expired Biogit must be disposed of according to local pharmaceutical waste regulations. The product must not be thrown away via wastewater (such as sinks or toilets) or into regular household trash. Patients are instructed to return the product to a designated drug take-back location or pharmacy when available.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Biogit found in:

A-Z Index: